TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03026543

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary Recruitment Maneuver

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ventilator
Study: NCT01614769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Two gross-matched glimepiride placebo tablets taken on Day -1 and Day 1 of the three treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Two gross-matched glimepiride placebo tablets taken on Day -1 and Day 1 of the three treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Two gross-matched glimepiride placebo tablets taken on Day -1 and Day 1 of the three treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Two gross-matched glimepiride placebo tablets taken on Day -1 and Day 1 of the three treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Two gross-matched glimepiride placebo tablets taken on Day -1 and Day 1 of the three treatment periods.
Study: NCT00472953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled human insulin
Description: Treat-to-target dose titration scheme, pre-prandial, inhalation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Treat-to-target dose titration scheme, pre-prandial, injection s.c.
Study: NCT03110796

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dressing with LU3103209 - Dose 1
Description: Dressing with LU3103209 - Dose 1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dressing with LU3103209 - Dose 2
Description: Dressing with LU3103209 - Dose 2

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Dressing without LU3103209
Description: Dressing without LU3103209
Study: NCT03355196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LRX712
Description: Ascending single dose on Day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ascending single dose on Day 1
Study: NCT01813435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Comparison of 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor monotherapy versus 12 months of standard dual anti platelet therapy (DAPT) followed by aspirin monotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Comparison of 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor monotherapy versus 12 months of standard dual anti platelet therapy (DAPT) followed by aspirin monotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid
Description: Comparison of 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor monotherapy versus 12 months of standard dual anti platelet therapy (DAPT) followed by aspirin monotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic Acid
Description: Comparison of 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor monotherapy versus 12 months of standard dual anti platelet therapy (DAPT) followed by aspirin monotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Active Comparator: Reference treatment strategy Acute Coronary Syndrome (ACS) patients incl. unstable angina (UA) patients: ASA and Brilique(ticagrelor) for 12 months followed by 12 months of ASA monotherapy.~Stable Coronary Artery Disease (CAD) patients: ASA and clopidogrel for 12 months followed by 12 months of ASA monotherapy
Study: NCT02419625

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: questionnaires
Description: questionnaires , serum samples will be used
Study: NCT02598245

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TOT 8/4
Description: placement of transobturator sling according to the TOT 8/4 technique

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TOT 6/3
Description: placement of transobturator sling according to the TOT 6/3 technique
Study: NCT03300908

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project ADHERE
Description: This is a 3-session ART medication adherence and risk reduction intervention. Participants are educated about the importance of staying healthy and taking their medication as prescribed; to discuss importance of improved immune functioning and what their viral load means; reminded that they can still infect others with HIV, and that there currently is no cure for HIV; expected to generate strategies to overcome adherence barriers; educated about sexually transmitted infections (STI)/HIV transmission modes; assisted in devising an appropriate medication adherence and risk reduction plan. Participants will report their progress and discuss challenges experienced when implementing their medication adherence and risk reduction plans while establishing short- and long-term goals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MACE
Description: This one-session medication adherence intervention covers the following content: 1) a discussion on what viral load represents and what HIV does to the body; 2) referral to a provider for participants without a provider; 3) the importance of maintaining regular contact with a health care provider; and 4) benefits of being retained in care.
Study: NCT05193773

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multifactorial interventions
Description: The experimental group underwent multifactorial interventions to reduce physical restraint, including developing routines for physical restraint, promoting institutional policies to reduce the use of physical restraint, developing alternative methods, education, and consultations.
Study: NCT02333188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02546050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT03299465

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: This is a single arm study and all participants will be assigned to a six-week restorative yoga intervention. Restorative yoga sessions will consist of gentle physical poses (asanas), breathing control (pranayama), and relaxation (savasana).
Study: NCT01816074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vyvanse (lisdexamphetamine)
Description: Active ADHD drug, Vyvanse, is administered to mother.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vyvanse (lisdexamphetamine)
Description: Active ADHD drug, Vyvanse, is administered to mother.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vyvanse (lisdexamphetamine)
Description: Active ADHD drug, Vyvanse, is administered to mother.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Parent Training
Description: Mother is given 8 weeks of individual sessions of behavioral parent training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Parent Training
Description: Mother is given 8 weeks of individual sessions of behavioral parent training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Parent Training
Description: Mother is given 8 weeks of individual sessions of behavioral parent training
Study: NCT02938429

Intervention type: OTHER
Group type: OTHER
Intervention: Physical activity measures via Actigraph GT3X+ accelerometers for 7 consecutive days

Intervention type: OTHER
Group type: OTHER
Intervention: Physical activity measures via Actigraph GT3X+ accelerometers for 7 consecutive days
Study: NCT03191422

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LSVT BIG
Description: LSVT BIG is a motor learning based intervention 4 hour long sessions per week for 4 weeks following a specific protocol. Each session is composed of exercises and participant specific activities, as well as a homework program.
Study: NCT03869983

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Omnipaque™ (iohexol) Injection
Description: 755 mg/mL iohexol (350 mgI/mL), 80 mL infused intravenously over approximately 20 seconds

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CE-Iohexol
Description: 755 mg/mL iohexol (350 mgI/mL)/50 mg CAPTISOL®/mL, 80 mL infused intravenously over approximately 20 seconds
Study: NCT03576612

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdV-tk
Description: Given IT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdV-tk
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Description: Given PO days 1-14; 1-3 days post surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Description: Given PO days 1-14; 1-3 days post surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Undergo RT, 60Gy in 30 daily fractions M-F for 6weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Undergo RT, 60Gy in 30 daily fractions M-F for 6weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO during RT 75mg/m2 daily during RT Post RT cycle 1: 150mg/m2 days 1-5 150mg/m2 cycle 2-6: days 1-5 (150-200mg/m2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO during RT 75mg/m2 daily during RT Post RT cycle 1: 150mg/m2 days 1-5 150mg/m2 cycle 2-6: days 1-5 (150-200mg/m2)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: day 15 post surgery 240mg IV q2wks x 26 doses , up to 52 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: day 15 post surgery 240mg IV q2wks x 26 doses , up to 52 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: correlative studies
Study: NCT02061774

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 1 gram of intravenous Acetaminophen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: placebo comparator .9% NaCl (sodium chloride) 100 mL over will be administered intravenously over a period of 15 minutes, 15 minutes (+/- 10 minutes) prior to the anticipated time of incision and every 6 hours (+/- 30 minutes) after the initial dose for 24 hours
Study: NCT01529047

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Feedback Intervention
Description: Printed or electronic form containing personalized information about health-relevant behaviors

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Feedback Intervention
Description: Printed or electronic form containing personalized information about health-relevant behaviors
Study: NCT00889408

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DT2219ARL
Description: anti-CD19/CD22 bispecific ligand-directed toxin DT2219ARL
Study: NCT03154593

Intervention type: OTHER
Intervention: Stage 2 - Bariatric Surgery
Description: This observational study follows patients after routine bariatric surgery.
Study: NCT03764007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Fluorocholine
Description: Given intravenously

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: Imaging technique that uses radioactive agents known as radiotracers to visualize and measure changes in metabolic processes, and in other physiological activities
Study: NCT01115361

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family planning for postpartum women
Description: A.Group education sessions regarding pregnancy risk, benefits of FP, and family planning options during the postpartum period.~B. IEC materials that deliver messages about the benefits of spacing pregnancies by at least 2 years, LAM, return to fecundity and pregnancy risk during the postpartum period and contraceptive options for postpartum women.~C. Use of a screening tool to assess pregnancy risk for postpartum women coupled with a brief counseling message and referral to FP services.~D.Convenient offer of FP services to women attending vaccination services for their infants.
Study: NCT02764333

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TPIV200

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Study: NCT00817544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741
Description: 3 mg of ORM-12741 as a single dose. Contains 0.73 mg (2.5 MBq) 14C labelled ORM-12741
Study: NCT01428271

Intervention type: OTHER
Intervention: Ultrasonography
Description: The confirmation of the real site of the sacral hiatus by ultrasonography
Study: NCT00906620

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QPR: question, persuade and refer (SEYLE)
Description: The QPR prevention program will be used in two modules, one for school staff and one for parents. According to the US Surgeon General's National Strategy for Suicide Prevention (2001), key gatekeepers are people who regularly come into contact with individuals or families in distress and gatekeeper training has been identified as one of a number of promising prevention strategies.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QPR: question, persuade and refer (SEYLE)
Description: The QPR prevention program will be used in two modules, one for school staff and one for parents. According to the US Surgeon General's National Strategy for Suicide Prevention (2001), key gatekeepers are people who regularly come into contact with individuals or families in distress and gatekeeper training has been identified as one of a number of promising prevention strategies.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QPR: question, persuade and refer (SEYLE)
Description: The QPR prevention program will be used in two modules, one for school staff and one for parents. According to the US Surgeon General's National Strategy for Suicide Prevention (2001), key gatekeepers are people who regularly come into contact with individuals or families in distress and gatekeeper training has been identified as one of a number of promising prevention strategies.
Study: NCT00957229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0449
Description: capsule, 150 mg, one pill daily, 18 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GDC-0449
Description: capsule, 150 mg, one pill daily, 18 months
Study: NCT00413491

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MR mammography
Description: MR mammography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MR
Description: MR
Study: NCT01757509

Intervention type: OTHER
Group type: OTHER
Intervention: Intervention group
Description: Participants will attend eight weeks of set dancing classes. Each class will be one and a half hours. Family members or volunteers will partner each participant with Parkinson's disease. The class will be led by a Chartered Physiotherapist who is also a set dancing teacher. Set dancing steps and sets will be thought and progressed in line with the participants' abilities. Frequent rests will be taken during the class.~Participants will be given a home exercise programme which will involve mental rehearsal, listening to music, watching dance DVD's and practicing dance material in the seated position to reduce the risk of falling.
Study: NCT01564875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvast CR
Description: Simvast CR Tab 20mg, 1 tablet once daily to be administered between 6 and 9 a.m.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zocor
Description: Zocor Tab 20mg, 1 tablet once daily to be administered between 6 and 9 p.m.
Study: NCT03864484

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iPad Application + Usual Rehabilitation
Description: The experimental group receives usual rehabilitation. In addition, the experimental group will watch movies using the iPad application for 3 minutes, once daily for 5 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual rehabilitation
Description: The control group receives usual rehabilitation.
Study: NCT01250002

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will receive the same volume of saline infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine administration 1.5 mg/kg bolus followed by a 2 mg/kg/hr infusion via intravenous catheter
Study: NCT00651885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treprostinil dienthanolmine sustained release
Description: UT-15C SR 1mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02430181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lonafarnib
Description: antiviral farnesyl transferase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lonafarnib
Description: antiviral farnesyl transferase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lonafarnib
Description: antiviral farnesyl transferase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lonafarnib
Description: antiviral farnesyl transferase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lonafarnib
Description: antiviral farnesyl transferase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lonafarnib
Description: antiviral farnesyl transferase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lonafarnib
Description: antiviral farnesyl transferase inhibitor
Study: NCT04431635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Copanlisib IV: day 1, 8, 15 every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab IV: Cycle 1 days 1 and 15; then day 1 only
Study: NCT02430181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a
Description: immunomodulator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a
Description: immunomodulator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a
Description: immunomodulator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: CYP 3A4 inhibitor, lonafarnib booster
Study: NCT02588482

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-density electroencephalography
Description: Auditory stimulations during electroencephalography recording

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional electroencephalography
Description: Auditory stimulations during electroencephalography recording
Study: NCT03054220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 5 MG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 5 MG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol 10 mg
Study: NCT04431635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab IV: Cycle 1 days 1, 8, 15, 22; then day 1 (C2-6); then Q2 cycles (8-12)
Study: NCT04478708

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: maridebart cafraglutide
Description: Participants will receive maridebart cafraglutide as a single dose in Part A and multiple doses in Part B and C.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: maridebart cafraglutide
Description: Participants will receive maridebart cafraglutide as a single dose in Part A and multiple doses in Part B and C.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: maridebart cafraglutide
Description: Participants will receive maridebart cafraglutide as a single dose in Part A and multiple doses in Part B and C.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo as a single dose in Part A and multiple doses in Part B.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo as a single dose in Part A and multiple doses in Part B.
Study: NCT03088852

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Citrate 100 MG
Description: initial intravenous treatment: Patients with magnesium levels 1-1.5 mg/dL will receive 2-4 grams of magnesium sulfate in the first 24 hours. Patients with magnesium levels 1.6-1.9 mg/dL will receive 1 gram of magnesium sulfate. participants with magnesium level ≥1 mg/dL, will be randomized, and oral magnesium therapy, Magnesium Citrate, ( or no treatment) will be started, and continued for at least three months. The experimental group will receive 400mg magnesium daily in two divided doses.
Study: NCT02073136

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet with phosphate containing additives

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet without phosphate containing additives
Study: NCT03935841

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 3-OHB salt (NaCl)
Description: 36 gram 3-OHB salt diluted in 500 ml sterile water
Study: NCT03054220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine 60mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine 60mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg
Study: NCT00459264

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Folic acid oral solution 2.5mg/5ml daily for up to 3 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for folic acid oral solution (2.5mg/5ml)